Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Leverson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Molecular Cell|July 11, 1998
Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanismJ D Leverson, S A Ness
The Journal of Biological Chemistry|June 22, 2000
The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7H k Huang, C A Joazeiro, E Bonfoco, et al.
Molecular Biology of the Cell|July 11, 2000
The APC11 RING-H2 finger mediates E2-dependent ubiquitinationJ D Leverson, C A Joazeiro, A M Page, et al.
Science (New York, N.Y.)|October 9, 1999
The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligaseC A Joazeiro, S S Wing, H Huang, et al.
Blood Cancer Journal|November 14, 2015
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)D C Phillips, Y Xiao, L T Lam, et al.
Oncogene|December 7, 2010
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell linesH Zhang, S Guttikonda, L Roberts, et al.
Oncogene|March 6, 2007
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibitionE K-H Han, J D Leverson, T McGonigal, et al.
Molecular Cell|November 11, 1998
Pim-1 kinase and p100 cooperate to enhance c-Myb activityJ D Leverson, P J Koskinen, F C Orrico, et al.
Oncogene|October 26, 2005
RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitorsS Morgan-Lappe, K W Woods, Q Li, et al.
British Journal of Pharmacology|May 26, 2012
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivoS Ackler, M J Mitten, J Chen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Molecular Cell|July 11, 1998
Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanismJ D Leverson, S A Ness
The Journal of Biological Chemistry|June 22, 2000
The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7H k Huang, C A Joazeiro, E Bonfoco, et al.
Molecular Biology of the Cell|July 11, 2000
The APC11 RING-H2 finger mediates E2-dependent ubiquitinationJ D Leverson, C A Joazeiro, A M Page, et al.
Science (New York, N.Y.)|October 9, 1999
The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligaseC A Joazeiro, S S Wing, H Huang, et al.
Blood Cancer Journal|November 14, 2015
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)D C Phillips, Y Xiao, L T Lam, et al.
Oncogene|December 7, 2010
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell linesH Zhang, S Guttikonda, L Roberts, et al.
Oncogene|March 6, 2007
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibitionE K-H Han, J D Leverson, T McGonigal, et al.
Molecular Cell|November 11, 1998
Pim-1 kinase and p100 cooperate to enhance c-Myb activityJ D Leverson, P J Koskinen, F C Orrico, et al.
Oncogene|October 26, 2005
RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitorsS Morgan-Lappe, K W Woods, Q Li, et al.
British Journal of Pharmacology|May 26, 2012
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivoS Ackler, M J Mitten, J Chen, et al.
Pageof 2